Received May 8, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | m77cc | IM |
Hives; tiredness; This non-serious case was reported by a other health professional via patient support programs and described the occurrence of hives in a 20-year-old male patient who received DTPa (Reduced antigen) (Tdap Vaccine) (batch number m77cc) for prophylaxis. On 07-MAR-2025, the patient received Tdap Vaccine (intramuscular). On 14-MAR-2025, 7 days after receiving Tdap Vaccine, the patient experienced hives (Verbatim: Hives). In MAR-2025, the patient experienced tiredness (Verbatim: tiredness). The patient was treated with prednisone. The outcome of the hives was resolving and the outcome of the tiredness was not reported. It was unknown if the reporter considered the hives and tiredness to be related to Tdap Vaccine. It was unknown if the company considered the hives and tiredness to be related to Tdap Vaccine. Additional Information: GSK Receipt Date: 28-MAR-2025 Hives lasting about an hour, then migrating to different locations for a week. Treated with prednisone and antihistamines with resolution of hives. Experiencing tiredness requiring frequent sleeping but is improving.